Pharmalittle: Novartis exec sold stock before FDA announced data scandal; FDA OKs fewer new generics this year

first_img Good morning, everyone, and welcome to another working week. We hope the weekend respite — or holiday break, for some — was invigorating and refreshing, because the oh-so-familiar routine of meetings, deadlines, conference calls, and the like has, of course, returned. But what can you do? The world keeps spinning, no matter what. So on that note, please join us for a needed cup or three of stimulation — we fancy butter pecan today, if suggestions are needed — and enjoy the menu of tidbits assembled for you. Hope you have a smashing day and, as always, please do keep in touch …An unnamed Novartis (NVS) executive sold $946,000 worth of shares less than three weeks before the Food and Drug Administration announced data from tests of its Zolgensma gene therapy were manipulated, Reuters writes. The stock sale by an executive member of the board or executive committee was disclosed in a July 19 Swiss stock exchange filing. Novartis says “the transaction was thoroughly checked beforehand and then approved accordingly. The person in question was not in possession of relevant material information.” GET STARTED Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED Pharmalot @Pharmalot By Ed Silverman Aug. 19, 2019 Reprints [email protected] Pharmalittle: Novartis exec sold stock before FDA announced data scandal; FDA OKs fewer new generics this year Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.center_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Alex Hogan/STAT What is it? About the Author Reprints Log In | Learn More What’s included? Ed Silverman Tags drug pricinggovernment agenciesMedicarepharmaceuticalspharmalittleSTAT+last_img

Leave a Reply

Your email address will not be published. Required fields are marked *